This report provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in irritable bowel syndrome partnering deals
- Top irritable bowel syndrome deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Irritable Bowel Syndrome Partnering 2007-2012 provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of irritable bowel syndrome partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors irritable bowel syndrome technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 30 links to online copies of actual irritable bowel syndrome deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of irritable bowel syndrome partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in irritable bowel syndrome partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading irritable bowel syndrome deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of irritable bowel syndromepartnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of irritable bowel syndrome technologies and products.
Report scope
Irritable Bowel Syndrome Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to irritable bowel syndrome trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
•Trends in irritable bowel syndrome dealmaking in the biopharma industry since 2007
•Access to summary headline, upfront, milestone and royalty data
•Access to over 30 irritable bowel syndrome contract documents
•The leading irritable bowel syndrome deals by value since 2007
In Irritable Bowel Syndrome Partnering 2007-2012, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Irritable Bowel Syndrome Partnering 2007-2012 provides the reader with the following key benefits:
- In-depth understanding of irritable bowel syndrome reflux deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 30 actual irritable bowel syndrome deals entered into by the world’s biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies